X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6670) 6670
Newsletter (40) 40
Magazine Article (4) 4
Dissertation (3) 3
Newspaper Article (2) 2
Report (2) 2
Transcript (2) 2
Book Chapter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6151) 6151
male (4425) 4425
female (4275) 4275
etoposide - administration & dosage (3814) 3814
antineoplastic combined chemotherapy protocols - therapeutic use (3647) 3647
middle aged (3638) 3638
oncology (3592) 3592
adult (3524) 3524
antineoplastic combined chemotherapy protocols - adverse effects (3213) 3213
etoposide (2792) 2792
aged (2704) 2704
chemotherapy (2532) 2532
etoposide - adverse effects (2395) 2395
cisplatin - administration & dosage (1627) 1627
treatment outcome (1613) 1613
cancer (1459) 1459
adolescent (1433) 1433
hematology (1308) 1308
lung neoplasms - drug therapy (1291) 1291
cisplatin (1240) 1240
cyclophosphamide - administration & dosage (1239) 1239
antineoplastic combined chemotherapy protocols - administration & dosage (1103) 1103
combined modality therapy (1065) 1065
drug administration schedule (930) 930
cisplatin - adverse effects (899) 899
etoposide - therapeutic use (890) 890
doxorubicin - administration & dosage (888) 888
vincristine - administration & dosage (855) 855
child (838) 838
survival rate (826) 826
therapy (795) 795
carboplatin - administration & dosage (787) 787
disease-free survival (739) 739
survival analysis (738) 738
cyclophosphamide (727) 727
prognosis (727) 727
remission induction (723) 723
neoplasm staging (682) 682
child, preschool (666) 666
carcinoma, small cell - drug therapy (665) 665
retrospective studies (654) 654
cyclophosphamide - adverse effects (644) 644
carboplatin (621) 621
cytarabine - administration & dosage (618) 618
transplantation (592) 592
ifosfamide - administration & dosage (583) 583
follow-up studies (571) 571
care and treatment (561) 561
aged, 80 and over (550) 550
bleomycin - administration & dosage (542) 542
trial (519) 519
survival (499) 499
dose-response relationship, drug (486) 486
doxorubicin - adverse effects (470) 470
carcinoma (469) 469
doxorubicin (461) 461
lung neoplasms - pathology (461) 461
antineoplastic agents - adverse effects (460) 460
infant (457) 457
toxicity (455) 455
vincristine - adverse effects (449) 449
young adult (448) 448
radiotherapy (440) 440
pharmacology & pharmacy (432) 432
carboplatin - adverse effects (430) 430
transplantation, autologous (424) 424
prospective studies (420) 420
recurrence (415) 415
tumors (414) 414
salvage therapy (412) 412
bleomycin - adverse effects (407) 407
children (404) 404
medicine & public health (404) 404
lung neoplasms - mortality (402) 402
carcinoma, non-small-cell lung - drug therapy (397) 397
phase-ii (396) 396
methotrexate - administration & dosage (395) 395
combination chemotherapy (379) 379
prednisone - administration & dosage (371) 371
risk factors (368) 368
testicular neoplasms - drug therapy (368) 368
ifosfamide (366) 366
neutropenia - chemically induced (357) 357
pediatrics (355) 355
lymphoma, non-hodgkin - drug therapy (352) 352
research (348) 348
administration, oral (346) 346
antineoplastic agents - therapeutic use (342) 342
hematopoietic stem cell transplantation (342) 342
time factors (342) 342
drug evaluation (327) 327
combination (326) 326
ifosfamide - adverse effects (324) 324
vincristine (317) 317
hodgkin disease - drug therapy (316) 316
disease (308) 308
antineoplastic agents - administration & dosage (306) 306
immunology (304) 304
bone-marrow transplantation (302) 302
lung cancer (299) 299
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6418) 6418
Japanese (167) 167
German (78) 78
Chinese (54) 54
French (54) 54
Spanish (26) 26
Russian (15) 15
Polish (12) 12
Hungarian (8) 8
Portuguese (8) 8
Italian (7) 7
Czech (4) 4
Dutch (3) 3
Danish (2) 2
Serbian (2) 2
Hebrew (1) 1
Korean (1) 1
Norwegian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | Radiotherapy Dosage | no | Doxorubicin/adverse effects | Etoposide/adverse effects | Procarbazine/adverse effects | Prospective Studies | Hodgkin Disease/drug therapy | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Positron-Emission Tomography | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Prednisone/adverse effects | Treatment Failure | Adolescent | Survival Analysis | Adult | Female | Cyclophosphamide/adverse effects | Vincristine/adverse effects | Neoplasm Staging | Bleomycin/adverse effects | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Hodgkin Disease - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - therapeutic use | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer
Journal Article
04/2000, Volume 22, Issue 4, 40
Cytostatic antibiotics of the anthracycline class are the best known of the chemotherapeutic agents that cause cardiotoxicity. Alkylating agents such as... 
Mitomycin, adverse reactions | Tretinoin, adverse reactions | Etoposide, adverse reactions | Cladribine, adverse reactions | Heart disorders, drug-induced | Pentostatin, adverse reactions | Vinca alkaloids, adverse reactions | Cytostatic antibiotics, adverse reactions | Fluorouracil, adverse reactions | Asparaginase, adverse reactions | Cisplatin, adverse reactions | Carmustine, adverse reactions | Amsacrine, adverse reactions | Ifosfamide, adverse reactions | Mitoxantrone, adverse reactions | Cyclophosphamide, adverse reactions | Cytarabine, adverse reactions | Paclitaxel, adverse reactions | Teniposide, adverse reactions | Antineoplastics, adverse reactions | Busulfan, adverse reactions | Chlormethine, adverse reactions | HEMOLYTIC-UREMIC SYNDROME | SOFT-TISSUE SARCOMAS | HAIRY-CELL LEUKEMIA | PHASE-II TRIAL | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | BONE-MARROW TRANSPLANTATION | HIGH-DOSE CYCLOPHOSPHAMIDE | SOUTHWEST-ONCOLOGY-GROUP | ACUTE LYMPHOBLASTIC-LEUKEMIA | METASTATIC BREAST-CANCER | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CONGESTIVE-HEART-FAILURE | Antineoplastic Agents - adverse effects | Humans | Risk Factors | Antimetabolites, Antineoplastic - adverse effects | Antibiotics, Antineoplastic - adverse effects | Heart Diseases - prevention & control | Antineoplastic Agents, Alkylating - adverse effects | Heart Diseases - chemically induced | Angiogenesis Inhibitors - adverse effects
Book Review
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 3, pp. 203 - 212
.... BEACOPP therapy was associated with higher initial rates of complete response and freedom from relapse but also with more short-term and long-term toxic effects... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease
Journal Article
Chest, ISSN 0012-3692, 02/2008, Volume 133, Issue 2, pp. 528 - 538
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 2, pp. 231 - 239
Purpose To optimize fertility advice in patients with Hodgkin lymphoma (HL) before therapy and during survivorship, information on the impact of chemotherapy... 
INHIBIN-B | PRESERVATION | OUTCOME MEASURE | OVARIAN RESERVE | ONCOLOGY | TERM FOLLOW-UP | DISEASE | FEMALE CANCER SURVIVORS | ANTI-MULLERIAN HORMONE | CHEMOTHERAPY | SERUM MARKER | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Gonadotropin-Releasing Hormone - analogs & derivatives | Fertility - physiology | Fertility Preservation | Young Adult | Vinblastine - adverse effects | Follicle Stimulating Hormone - blood | Hodgkin Disease - drug therapy | Oligospermia - epidemiology | Vincristine - administration & dosage | Adult | Female | Gonadotropin-Releasing Hormone - therapeutic use | Hodgkin Disease - physiopathology | Inhibins - blood | Menstrual Cycle - drug effects | Testosterone - blood | Menstrual Cycle - physiology | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Survivors | Etoposide - administration & dosage | Ovary - physiology | Hodgkin Disease - epidemiology | Bleomycin - administration & dosage | Bleomycin - adverse effects | Germany - epidemiology | Randomized Controlled Trials as Topic | Pregnancy | Testis - physiology | Hodgkin Disease - blood | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 2015, Volume 169, Issue 5, pp. 672 - 682
... (n = 24) were 33% (95% CI, 16–55%) and 75%, respectively. Grade ≥ 3 treatment‐emergent adverse events, including anaemia, thrombocytopenia, lymphopenia... 
mogamulizumab | randomized phase II study | CCR4 | adult T‐cell leukaemia‐lymphoma | antibody therapy | Adult T-cell leukaemia-lymphoma | Mogamulizumab | Antibody therapy | Randomized phase II study | adult T-cell leukaemia-lymphoma | MONOCLONAL-ANTIBODY KW-0761 | RECEPTOR | LEUKEMIA/LYMPHOMA | HEMATOLOGY | EXPRESSION | ASSOCIATION | TRANSPLANTATION | Doxorubicin - therapeutic use | Nitrosourea Compounds - adverse effects | Prednisolone - adverse effects | Nitrosourea Compounds - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Carboplatin - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Leukemia-Lymphoma, Adult T-Cell - drug therapy | Carboplatin - therapeutic use | Vindesine - adverse effects | Vindesine - therapeutic use | Aged, 80 and over | Adult | Female | Prednisolone - therapeutic use | Etoposide - adverse effects | Leukemia-Lymphoma, Adult T-Cell - mortality | Etoposide - therapeutic use | Treatment Outcome | Leukemia-Lymphoma, Adult T-Cell - pathology | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Doxorubicin - adverse effects | Chemotherapy | Lymphomas | T cells | Leukemia | Cancer | Haematological Malignancy | Research Paper
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 6, pp. 684 - 691
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 33, pp. 4117 - 4123
Purpose Although the outcome of patients with HIV-related Hodgkin lymphoma (HIV-HL) has markedly improved since the introduction of combined antiretroviral... 
SURVIVAL | PROGNOSTIC-FACTORS | ONCOLOGY | ACTIVE ANTIRETROVIRAL THERAPY | DISEASE | STANFORD-V | RADIOTHERAPY | STEM-CELL TRANSPLANTATION | PATIENTS PTS | IMMUNODEFICIENCY | CHEMOTHERAPY | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Hodgkin Disease - pathology | Humans | Lymphoma, AIDS-Related - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Hodgkin Disease - radiotherapy | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Lymphoma, AIDS-Related - drug therapy | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Bleomycin - administration & dosage | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | HIV Infections - complications | Lymphoma, AIDS-Related - radiotherapy | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 368, Issue 15, pp. 1408 - 1416
A dose-intense infusional chemotherapy program plus rituximab had a high degree of efficacy in patients with primary mediastinal B-cell lymphoma, which is... 
MEDICINE, GENERAL & INTERNAL | AMPLIFICATION | MANAGEMENT | EFFICACY | DOXORUBICIN | SCLEROSIS | CLASSICAL HODGKIN LYMPHOMA | RADIOTHERAPY | EXPRESSION | GERMINAL-CENTER | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Filgrastim | Dose-Response Relationship, Drug | Young Adult | Vincristine - administration & dosage | Adult | Female | Retrospective Studies | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Kaplan-Meier Estimate | Rituximab | Stroke Volume - drug effects | Etoposide - administration & dosage | Recombinant Proteins - administration & dosage | Disease-Free Survival | Vincristine - adverse effects | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Drugs | Dose-response relationship (Biochemistry) | Usage | Cyclophosphamide | Patient outcomes | Dosage and administration | Lymphomas | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Doxorubicin | Medical research | Nuclear magnetic resonance--NMR | Disease | Review boards | Genes | Etoposide | Prednisone | Radiation therapy | Kinases | Vincristine | Patients | Morbidity | Chemotherapy | Lymphocytes B | Remission | Mutation | Hodgkin's disease | B-cell lymphoma
Journal Article